ETST Earth Science Tech

Earth Science Tech, Inc., Reports its June 30, 2024, Quarter Results, Recording Over $8.5M in Revenue and $1.07M in Net Profit

Earth Science Tech, Inc., Reports its June 30, 2024, Quarter Results, Recording Over $8.5M in Revenue and $1.07M in Net Profit

Miami, FL, July 29, 2024 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or “Company”), a holding entity currently focused on the health and wellness industry, today shares its financial results from its .

For the three-month quarter ended June 30, 2024, the Company recorded:

  • $1,384,407 in Cash, versus $91,989 in the quarter ended June 30, 2023, a $1,292,418 increase. Resulting in a 1,404.97% improvement between both periods.



  • $4,772,247 in Total Assets, versus $2,945,143 in the quarter ended June 30, 2023, a $1,827,104 increase. Resulting in a 62.04% improvement between both periods.



  • $8,568,918 in Revenue, versus $219,934 in the quarter ended June 30, 2023, a $8,348,984 increase. Resulting in a 3,796.13% improvement between both periods.



  • $6,410,434 in Gross Profit, versus $148,769 in the quarter ended June 30, 2023, a $6,261,665 increase. Resulting in a 4,208.99 % improvement between both periods.



  • $1,076,254 in Net Profit, versus a loss of $35,596 in the quarter ended June 30, 2023, a $1,111,850 increase. Resulting in a 3,123.53% improvement between both periods.

About Earth Science Tech, Inc.

Earth Science Tech, Inc. is a holding entity currently in compounding pharmaceuticals and telemedicine through its wholly owned subsidiaries RxCompoundStore.com, LLC., Peaks Curative, LLC. and Earth Science Foundation, Inc.

To learn more, please visit: 

RxCompoundStore.com, LLC.

RxCompound is a complete compounding pharmacy. RxCompound is currently licensed to fulfill prescriptions in the states of Delaware, Florida, Pennsylvania, New York, Arizona, New Jersey, Wisconsin, Minnesota, Rhode Island, Utah, Georgia, Nevada, Massachusetts, Missouri, Iowa, Maryland, Ohio, Colorado, North Carolina, Maine, Indiana and Illinois. RxCompound is in the application process to obtain licenses in the remaining states in which it is not yet approved to ship prescriptions.

To learn more please visit: 

About Peaks Curative, LLC.

Peaks is the telemedicine referral site facilitating asynchronous consultations for branded compound medications prepared at RxCompound. Peaks is currently positioned to prescribe to all 50 states utilizing third-party consultation services, but only able to fulfill prescriptions within RxCompound’s licensed states. Peaks will be able to fulfill more states as RxCompound becomes licensed in additional states.

To learn more please visit: 

About Earth Science Foundation, Inc.

Earth Science Foundation Inc. is a favored entity of the Company, effectively being a non-profit organization that was incorporated on February 11, 2019, and is structured to accept grants and donations to help those in need of assistance in paying for prescriptions.

SAFE HARBOR ACT: Forward-looking statements are included within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding the Company’s expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations or listing on an exchange — including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will” and other similar expressions — are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond the Company’s control and may cause actual results, performance or achievements to differ materially from anticipated results, performance or achievements. The Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise. There are no assurances that the Company will complete additional acquisitions or will be successful in being approved for a NASDAQ listing. No information in this press release should be construed in any manner whatsoever as an indication of the future performance of the Company’s revenues, financial condition or stock price.

Company Contact:

Giorgio R. Saumat

CEO and Chairman of the Board

(305) 724-5684



EN
29/07/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Earth Science Tech

 PRESS RELEASE

Earth Science Tech, Inc. Announces Initiatives to Advance Public Compa...

Earth Science Tech, Inc. Announces Initiatives to Advance Public Company Strategy; Expects Approximately $1.4 Million in Annualized Savings and Fiscal 2026 Net Income Growth of More Than 40%, from $3.3 Million to $4.7 Million Outlines strategic portfolio actions, governance enhancements and capital discipline plans to support next phase of growth MIAMI, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic holding company focused on acquiring and scaling high-potential operating businesses, today announced that its Board of Director...

 PRESS RELEASE

Earth Science Tech, Inc. (ETST) Upgrades Audit Capabilities, Engages S...

Earth Science Tech, Inc. (ETST) Upgrades Audit Capabilities, Engages Semple, Marchal & Cooper, LLP as Independent PCAOB Auditor to Support Continued Expansion MIAMI, FL, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic holding company focused on a diversified, vertically integrated health and wellness portfolio, today announced the engagement of Semple, Marchal & Cooper, LLP (“Semple”) as its new independent Public Company Accounting Oversight Board (PCAOB) auditor. This transition represents a strategic upgrade in the Company’...

 PRESS RELEASE

Earth Science Tech, Inc. (ETST) Reports Third Fiscal Quarter 2026 Resu...

Earth Science Tech, Inc. (ETST) Reports Third Fiscal Quarter 2026 Results Revenue of $8.4 million, up 14.1% year-over-yearGross profit margin of 76.3%, up 71 bps year-over-yearNet income of $910,000, up 341% year-over-yearGenerated positive cash from operations of $1.2 million fiscal year-to-datePeaks, the company’s telemedicine platform, surpasses $2.0 million in revenue in less than a year, scaling from $248,000 into a high‑margin growth platformReduced outstanding shares of common stock by 3.6% year over year through share repurchasesGeographic expansion underway with up to 10 additional...

 PRESS RELEASE

Earth Science Tech, Inc. (ETST), to Report Financial Results for Fisca...

Earth Science Tech, Inc. (ETST), to Report Financial Results for Fiscal Third Quarter on February 17, 2026 MIAMI, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic holding company focused on acquiring and scaling high-potential operating businesses, today announced that it will report financial results for the three months ended December 31, 2025, after the close of trading on Tuesday, February 17, 2026. Investors with questions they would like addressed during the earnings call may submit them in advance at Conference Call In...

 PRESS RELEASE

Earth Science Tech, Inc. (ETST) Issues Directive Industry Classificati...

Earth Science Tech, Inc. (ETST) Issues Directive Industry Classification Update to SIC 2834; Formally Identifies as Pharmaceutical Entity Since 2022 MIAMI, FL, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic holding company, is issuing a formal directive to all financial data providers, news aggregators, and brokerage platforms to reconcile their databases with the Company’s established pharmaceutical operations. Following a fundamental strategic pivot initiated in 2022, the Company has fully transitioned away from legacy indu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch